Einzeltreffer — DigiBib

Objective: Anxiety is a prevalent comorbidity in lung cancer (LC) patients associated with a decline in quality of life. Dehydroepiandrosterone (DHEA), a neuroactive steroid, levels rise in response to stress. Prior research on the association between DHEA and anxiety has yielded contradictory results and no study has investigated this association in LC patients.

Methods: A total of 213 patients with LC were recruited from a general hospital. Data on demographic and cancer-related variables were collected. Using the Chinese version of the Hospital Anxiety and Depression Scale (HADS), the degree of anxiety was determined. Cortisol, DHEA, and Dehydroepiandrosterone sulfate (DHEA-S) levels in saliva were measured. Adjusting for confounding variables, a multivariate regression analysis was conducted.

Results: 147 men and 66 women comprised our group with an average age of 63.75 years. After accounting for demographic and treatment-related factors, anxiety levels were significantly correlated with, post-traumatic stress symptoms (PTSSs) (β = 0.332, p < 0.001) and fatigue (β = 0.247, p = 0.02). Association between anxiety and three factors, including DHEA, PTSSs, and fatigue, was observed in patients with advanced cancer stages (III and IV) (DHEA β = 0.319, p = 0.004; PTSS β = 0.396, p = 0.001; fatigue β = 0.289, p = 0.027) and those undergoing chemotherapy (DHEA β = 0.346, p = 0.001; PTSS β = 0.407, p = 0.001; fatigue β = 0.326, p = 0.011).

Conclusions: The association between anxiety and DHEA remained positive in advanced cancer stages and chemotherapy patients. Further study is necessary to determine whether DHEA is a potential biomarker of anxiety in LC patients.

Titel:	The associates of anxiety among lung cancer patients: Dehydroepiandrosterone (DHEA) as a potential biomarker.
Autor/in / Beteiligte Person:	Wu, JR ; Chen, VC ; Fang, YH ; Hsieh, CC ; Wu, SI
Link:	Zum Volltext
Zeitschrift:	BMC cancer, Jg. 24 (2024-04-15), Heft 1, S. 476
Veröffentlichung:	London : BioMed Central, [2001-, 2024
Medientyp:	academicJournal
ISSN:	1471-2407 (electronic)
DOI:	10.1186/s12885-024-12195-9
Schlagwort:	Male Humans Female Middle Aged Dehydroepiandrosterone Sulfate analysis Quality of Life Anxiety epidemiology Hydrocortisone Fatigue Biomarkers Dehydroepiandrosterone analysis Lung Neoplasms complications
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [BMC Cancer] 2024 Apr 15; Vol. 24 (1), pp. 476. <i>Date of Electronic Publication: </i>2024 Apr 15. MeSH Terms: Dehydroepiandrosterone* / analysis ; Lung Neoplasms* / complications ; Male ; Humans ; Female ; Middle Aged ; Dehydroepiandrosterone Sulfate / analysis ; Quality of Life ; Anxiety / epidemiology ; Hydrocortisone ; Fatigue ; Biomarkers References: J Cancer Res Clin Oncol. 2023 Aug;149(9):6371-6379. (PMID: 36757620) ; J Pain Symptom Manage. 2020 Sep;60(3):522-530.e1. (PMID: 32305577) ; Psychooncology. 2019 Jan;28(1):31-38. (PMID: 30264450) ; Psychooncology. 2018 Mar;27(3):791-801. (PMID: 29318702) ; Psychoneuroendocrinology. 2020 Sep;119:104751. (PMID: 32559611) ; Med Clin North Am. 2017 Nov;101(6):1099-1113. (PMID: 28992857) ; BMC Psychiatry. 2019 Sep 3;19(1):269. (PMID: 31481035) ; Adv Exp Med Biol. 2018;1023:29-36. (PMID: 28573442) ; World J Oncol. 2021 Jun;12(2-3):61-66. (PMID: 34046100) ; Front Psychiatry. 2019 May 16;10:352. (PMID: 31156487) ; Biochim Biophys Acta. 2015 Dec;1856(2):189-210. (PMID: 26297204) ; Psychoneuroendocrinology. 2019 Jun;104:259-268. (PMID: 30909007) ; Horm Behav. 2017 Mar;89:69-85. (PMID: 27979632) ; J Psychosom Res. 2013 Mar;74(3):244-7. (PMID: 23438716) ; J Fam Pract. 2001 Jan;50(1):19-25. (PMID: 11195476) ; J Cancer Surviv. 2022 Oct;16(5):988-997. (PMID: 34529261) ; Psychooncology. 2019 Dec;28(12):2382-2388. (PMID: 31679172) ; Arch Phys Med Rehabil. 2014 Aug;95(8):1533-9. (PMID: 24742938) ; Compr Psychiatry. 2003 Jan-Feb;44(1):78-81. (PMID: 12524640) ; Cancer Nurs. 2020 Jan/Feb;43(1):E54-E60. (PMID: 30601265) ; Asia Pac J Oncol Nurs. 2021 Jan 29;8(2):172-179. (PMID: 33688566) ; Psychoneuroendocrinology. 2012 Jul;37(7):929-36. (PMID: 22133517) ; Sci Rep. 2017 Jan 11;7:39397. (PMID: 28074915) ; Lancet Psychiatry. 2017 Apr;4(4):330-338. (PMID: 28109647) ; BMC Psychiatry. 2020 Aug 5;20(1):393. (PMID: 32758184) ; Horm Behav. 2017 Nov;96:104-115. (PMID: 28919553) ; Psychiatry Res. 1999 Oct 18;88(1):63-70. (PMID: 10641587) ; Aten Primaria. 1996 Oct 15;18(6):289-96. (PMID: 8983381) ; Anxiety Stress Coping. 2011 Jul;24(4):359-67. (PMID: 21253957) ; Eur J Oncol Nurs. 2016 Dec;25:16-23. (PMID: 27865248) ; J Pain Symptom Manage. 2004 Apr;27(4):322-32. (PMID: 15050660) ; J Cancer Surviv. 2018 Apr;12(2):178-185. (PMID: 29080061) ; Fam Pract. 2010 Dec;27(6):615-24. (PMID: 20622049) ; Breast Cancer. 2021 Jan;28(1):236-245. (PMID: 33030667) ; Psychooncology. 2018 Jun;27(6):1509-1516. (PMID: 29473255) ; Int J Hematol Oncol. 2019 Jul 11;8(2):IJH17. (PMID: 31467663) ; Psychooncology. 2015 Jun;24(6):624-34. (PMID: 25393527) ; J Pain Symptom Manage. 2018 Apr;55(4):1173-1178. (PMID: 29291932) ; J Clin Nurs. 2017 Oct;26(19-20):3137-3143. (PMID: 27875034) ; BMJ Support Palliat Care. 2021 Mar;11(1):32-39. (PMID: 31836594) ; Mol Psychiatry. 2020 Jul;25(7):1487-1499. (PMID: 31745237) ; Support Care Cancer. 2013 Jan;21(1):201-9. (PMID: 22669608) ; Int J Environ Res Public Health. 2022 Mar 14;19(6):. (PMID: 35329112) ; Sci Rep. 2022 Oct 3;12(1):16552. (PMID: 36192413) ; Crit Care Med. 2009 Dec;37(12):3114-9. (PMID: 19789447) ; J Behav Med. 2020 Aug;43(4):553-563. (PMID: 31435892) ; Acta Oncol. 2022 May;61(5):625-631. (PMID: 34889167) ; Cancer. 2020 Jul 15;126(14):3181-3191. (PMID: 32374431) ; BMJ. 2018 Apr 25;361:k1415. (PMID: 29695476) ; Psychooncology. 2017 Jan;26(1):74-80. (PMID: 26898732) ; PLoS One. 2014 May 09;9(5):e97183. (PMID: 24816642) ; Neuropsychiatr Dis Treat. 2020 Sep 17;16:2103-2109. (PMID: 32982248) ; Pain Med. 2007 Apr;8(3):223-34. (PMID: 17371409) ; Front Psychiatry. 2021 Jul 06;12:688367. (PMID: 34295276) ; Medicina (Kaunas). 2022 Apr 02;58(4):. (PMID: 35454346) ; Asian Pac J Cancer Prev. 2019 Oct 01;20(10):3015-3019. (PMID: 31653149) ; Cancer. 2019 Feb 1;125(3):353-364. (PMID: 30602059) ; Int J Behav Med. 2020 Jun;27(3):316-324. (PMID: 31858447) ; J Evid Based Complementary Altern Med. 2017 Jul;22(3):502-512. (PMID: 30208733) ; Qual Life Res. 2014 Apr;23(3):977-89. (PMID: 24081873) ; Depress Anxiety. 2017 Apr;34(4):327-339. (PMID: 27466972) ; Support Care Cancer. 2020 Aug;28(8):3921-3926. (PMID: 31858249) ; Cancer Manag Res. 2019 May 09;11:4347-4356. (PMID: 31190999) ; J Gen Intern Med. 2001 Sep;16(9):606-13. (PMID: 11556941) ; J Thorac Dis. 2016 Oct;8(10):2879-2884. (PMID: 27867564) ; Curr Oncol. 2022 Nov 15;29(11):8751-8766. (PMID: 36421342) ; Psychooncology. 2021 Jun;30(6):919-927. (PMID: 33724591) ; BMC Cancer. 2019 Oct 11;19(1):943. (PMID: 31604468) ; BMJ Open. 2020 Jul 13;10(7):e033211. (PMID: 32665341) Contributed Indexing: Keywords: Anxiety; Chemotherapy; Dehydroepiandrosterone (DHEA); Lung cancer (LC) Substance Nomenclature: 459AG36T1B (Dehydroepiandrosterone) ; 57B09Q7FJR (Dehydroepiandrosterone Sulfate) ; WI4X0X7BPJ (Hydrocortisone) ; 0 (Biomarkers) Entry Date(s): Date Created: 20240415 Date Completed: 20240417 Latest Revision: 20240425 Update Code: 20240425 PubMed Central ID: PMC11021003

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

The associates of anxiety among lung cancer patients: Dehydroepiandrosterone (DHEA) as a potential biomarker.